NCT05918640View on ClinicalTrials.gov

Lurbinectedin in FET-Fused Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 27, 2023

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2028

Conditions
Ewing SarcomaDesmoplastic Small Round Cell TumorPediatric CancerUndifferentiated Sarcoma
Interventions
DRUG

Lurbinectedin

Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.

Trial Locations (6)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

48109

RECRUITING

University of Michigan, Ann Arbor

52242

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

lead

Children's Hospital of Philadelphia

OTHER